Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 6,763 matching trials from the live ClinicalTrials.gov search.
Filters: Bethesda, Maryland Clear all
Completed No phase listed Observational

Positional Cloning of the Gene(s) Responsible for Alagille Syndrome

NCT00001642
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:47 AM EDT
Active, not recruiting Phase 3 Interventional

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
View directory record Official record
Conditions
Arteriosclerosis, Hypercholesterolaemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
14,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
132
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 6:47 AM EDT
Completed No phase listed Observational

Voriconazole Blood Levels and Toxicity

NCT00359541
View directory record Official record
Conditions
Pharmacology
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

NCT01851369
View directory record Official record
Conditions
Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer
Interventions
TRC102, CT scan, Lomotil, Prochlorperazine, Metoclopramide, 5-HT3 antagonist, Aprepitant, Biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

Extended Dosing With Eltrombopag for Severe Aplastic Anemia

NCT01891994
View directory record Official record
Conditions
Severe Aplastic Anemia (SAA)
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 22, 2026, 6:47 AM EDT
Recruiting Phase 1 Interventional

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880
View directory record Official record
Conditions
Epilepsy
Interventions
Mangafodipir, Gadolinium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 6:47 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 6:47 AM EDT
Terminated Phase 3 Interventional Results available

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

NCT02718417
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, paclitaxel, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
146
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 22, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

NCT00709618
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Vinorelbine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 22, 2026, 6:47 AM EDT
Terminated Not applicable Interventional Results available

Epidermal Coverage of Traumatic Wound Injuries Via Use of Autologous Spray Skin Applied Over Bilayered Wound Matrix

NCT02469168
View directory record Official record
Conditions
Wounds and Injury
Interventions
Recell, Control
Device · Procedure
Lead sponsor
Rubin, J. Peter, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 22, 2026, 6:47 AM EDT
Completed No phase listed Observational

Evaluation of Lipoproteins

NCT00001168
View directory record Official record
Conditions
Evaluation of Plasma Lipoproteins
Interventions
Balanced diet
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1979
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 2 Interventional

Leucovorin for the Treatment of 5 q Minus Syndrome

NCT00004997
View directory record Official record
Conditions
5q Minus Syndrome, Myelodysplastic Syndrome
Interventions
Leucovorin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes

NCT00005760
View directory record Official record
Conditions
Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women

NCT00006320
View directory record Official record
Conditions
HIV Infection
Interventions
determine blood levels of anti-HIV drugs
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 1Phase 2 Interventional

Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00005859
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
tipifarnib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 22, 2026, 6:47 AM EDT
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
158
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 1 Interventional

Diagnostic Effectiveness of Virtual Bronchoscopy

NCT00001515
View directory record Official record
Conditions
Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions
virtual bronchoscopy
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 2 Interventional

Study of LY300164 for the Treatment of Parkinson's Disease

NCT00004576
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
LY300164
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:47 AM EDT
Withdrawn Phase 2 Interventional

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

NCT06654050
View directory record Official record
Conditions
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions
alrizomadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074
View directory record Official record
Conditions
Multiple Myeloma
Interventions
elotuzumab, Lenalidomide, Dexamethasone, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Denver, Colorado • Bethesda, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 22, 2026, 6:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers

NCT00027482
View directory record Official record
Conditions
Healthy, HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 6:47 AM EDT
Recruiting No phase listed Observational

MEHMO Natural History and Biomarkers

NCT06019182
View directory record Official record
Conditions
Intellectual Disability, Epilepsy, Hypogonadisms, Microcephaly, Nervous System Malformations, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Week to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2053
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pathophysiology of Focal Hand Dystonia

NCT03223623
View directory record Official record
Conditions
Dystonia
Interventions
TMS, MRI, VASO Imaging
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 22, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

NCT00288080
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
245
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 22, 2026, 6:47 AM EDT